XOMA Royalty Corp

# XOMA Royalty Corp

XOMA Royalty Corporation operates as a biotech royalty aggregator, acquiring economic rights to milestone payments and royalty streams from pharmaceutical development partners. The company holds a portfolio of interests in both commercial and pre-commercial therapeutic candidates across various therapeutic areas. Its business model centers on licensing early to mid-stage clinical assets—primarily in Phase 1 and 2 development—to partners while retaining rights to future milestone and royalty payments, as well as acquiring royalty streams from late-stage or already-commercialized assets.

The company generates revenue through two primary streams: milestone payments triggered by development or regulatory achievements of its partnered assets, and ongoing royalties from successful commercial products. This structure allows XOMA to participate in the financial upside of partner-developed therapies without direct responsibility for development costs or manufacturing operations.

The company operates with a lean organizational structure of 13 full-time employees and maintains a geographically dispersed portfolio covering the United States and the Asia Pacific region. XOMA Royalty Corporation was incorporated in 1981 and is based in Emeryville, California. The company underwent a corporate restructuring in July 2024, when its parent entity changed its name from XOMA Corporation to XOMA Royalty Corporation to reflect the organization's pivot toward the royalty aggregation business model.